68

OBiO Technology (Shanghai) Corp. Ltd. A

688238 · SHG · Healthcare / Biotechnology

7.26CNY+0.39 (+5.68%)

Price History

Full chart

Market Stats

Previous Close6.87
Open7.10
Day Range7.10 – 7.65
52-Week Range5.01 – 9.33
Volume64.92M
Market Cap5.74B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.37
Dividend Yield0.00%
Beta0.48
50-Day Avg6.79
200-Day Avg6.74

About

Shanghai Obio Technology (Group) Corp., Ltd., a biotechnology company, engages in the provision of technical services for the field of regenerative medicine and anti-aging in China and internationally. The company offers customized plasmid design and viral vector packaging services; AAV serotypes and tissue-specific promoters to support scientific research; and research grade, NHP Grade, cGMP grade vector manufacturing process, for basic research, translational research and clinical trials. It also provides CDMO services encompassing process development, analytical methods, IND-enabling chemistry, manufacturing, and controls; and clinical and commercial manufacturing for viral vector, oncolytic virus, and cell therapy products, as well as engages in the production and sales of biological raw materials, biological agents, reagents, and other products. The company was formerly known as Obio Technology (Shanghai) Corp., Ltd. and change its name to Shanghai Obio Technology (Group) Corp., Ltd. in March 2026. The company was founded in 2013 and is headquartered in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Oudong Pan
  • Employees723
  • HeadquartersInternational Medical Park, Shanghai, China, 201321, China
  • Websitehttps://www.obiosh.com

Leadership

  • Mr. Oudong PanFounder & Chairman of the Board · b. 1968
  • Mr. Junyi PanGM & Director · b. 1994
  • Ms. Luyuan XuDeputy GM, Accounting Supervisor & Board Secretary · b. 1970
  • Ms. Shan YinDeputy GM & Director · b. 1982
  • Ms. Qingmei XiaDeputy General Manager · b. 1979
  • Ms. Qinbin WuDeputy General Manager · b. 1972
  • Ms. Jiali YangDeputy Director of R&D · b. 1986
  • Mr. Houliang WeiVice President of Process Development · b. 1988
  • Mr. Haizi ChengTechnical R&D Director · b. 1984
  • Ms. Suli LiuCDMO Project Manager · b. 1984

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue62.91M142.77M254.95M291.30M204.81M248.15M267.70M
Growth (%)-+126.93%+78.57%+14.26%-29.69%+21.16%+7.88%
Cost of Revenue38.43M59.81M124.07M161.93M217.86M341.97M306.57M
Gross Profit24.48M82.96M130.88M129.37M-13.05M-93.82M-38.87M
Gross Margin38.91%58.11%51.34%44.41%-6.37%-37.81%-14.52%
Operating Expense64.63M64.21M80.82M114.36M143.17M167.42M167.38M
Operating Income-40.15M18.75M50.06M15.01M-156.23M-261.24M-206.26M
Operating Margin-63.81%13.13%19.63%5.15%-76.28%-105.27%-77.05%
EBITDA-34.29M99.25M83.74M69.51M-114.43M-219.87M-127.37M
EBITDA Margin-54.50%69.52%32.85%23.86%-55.87%-88.60%-47.58%
Net Income-36.52M94.44M54.26M39.26M-127.94M-321.81M-235.06M
Net Income Margin-58.05%66.15%21.28%13.48%-62.47%-129.69%-87.81%
R&D23.80M21.98M23.62M34.83M50.87M47.33M48.75M
R&D as % of Total Revenue37.83%15.40%9.26%11.96%24.84%19.07%18.21%
Interest Expense2.56M2.48M2.98M2.76M6.83M7.45M8.61M
Interest Expense % of Total Revenue4.07%1.74%1.17%0.95%3.33%3.00%3.22%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets204.87M1.01B1.26B2.50B2.60B2.28B2.09B
Total Liabilities110.94M164.62M345.77M324.77M545.12M545.19M683.69M
Total Equity84.88M849.45M917.67M2.17B2.06B1.74B1.41B
Cash48.02M455.36M619.01M1.24B657.05M439.44M292.59M
Net Debt------93.93M

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-23.22M62.32M109.31M21.42M-90.12M-61.07M-102.59M
Capital Expenditure35.77M95.93M262.11M484.42M547.12M167.46M126.24M
Free Cash Flow-59.00M-33.61M-152.80M-462.99M-637.24M-228.53M-228.84M
Dividends Paid2.55M2.53M-5.10M5.02M6.37M8.35M
FCF to OCF254.05%-53.93%-139.79%-2161.06%707.09%374.21%223.05%
Dividend Paid to FCF-4.32%-7.52%--1.10%-0.79%-2.79%-3.65%

Earnings

Report DateApr 26, 2022Aug 24, 2022Oct 26, 2022Dec 31, 2022Apr 26, 2023
EPS Estimate-----
EPS Actual0.030.030.030.010.01
Surprise-----
TimingPre-marketAfter-hoursPre-market-Pre-market

Key Statistics & Ratios

Market Cap5.74B
Enterprise Value5.89B
Trailing P/E0.00
Forward P/E0.00
Price / Sales21.30
Price / Book4.31
EPS-0.37
Book Value2.08
Revenue (TTM)269.63M
Gross Profit (TTM)-35.51M
EBITDA-124.06M
Profit Margin-86.01%
Operating Margin-66.23%
Return on Equity-16.29%
Return on Assets-6.70%
Shares Outstanding649.04M
Shares Float450.56M
Beta0.48
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • May 30, 20231.3:1